TCGA-90-7766-01A-21R-2125-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 66
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.480
- G2M_CHECKPOINT+0.470
- MITOTIC_SPINDLE+0.380
- PI3K_AKT_MTOR_SIGNALING+0.300
- MYC_TARGETS_V1+0.260
- SPERMATOGENESIS+0.210
- MYC_TARGETS_V2+0.200
- DNA_REPAIR+0.190
- OXIDATIVE_PHOSPHORYLATION+0.170
- PROTEIN_SECRETION+0.100
Top 10 suppressed
- ANGIOGENESIS-0.600
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.560
- COAGULATION-0.450
- PANCREAS_BETA_CELLS-0.440
- CHOLESTEROL_HOMEOSTASIS-0.420
- MYOGENESIS-0.390
- HYPOXIA-0.370
- TGF_BETA_SIGNALING-0.360
- UV_RESPONSE_UP-0.310
- APICAL_JUNCTION-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R160 | — | — | 0.864 |
| 2 | SRR8942963 | — | — | 0.846 |
| 3 | TCGA-AR-A24H-01A-11R-A169-07 | — | B | 0.841 |
| 4 | TCGA-43-7658-01A-11R-2125-07 | — | cohortMD1 | 0.838 |
| 5 | TCGA-21-1080-01A-01R-0692-07 | — | cohortSQ1 | 0.833 |
| 6 | BS_2A5R9MEJ | high-grade glioma | — | 0.829 |
| 7 | R181 | — | — | 0.828 |
| 8 | SRR650192 | — | — | 0.827 |
| 9 | TCGA-E5-A4TZ-01A-11R-A31N-07 | — | — | 0.827 |
| 10 | SAMN03290898 | — | — | 0.826 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.480 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.170 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.070 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.070 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.050 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.020 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.020 | Idelalisib | — uncovered |